Intranasal gene therapy for the treatment of neurological disorders

Namdev Dhas; Tejal Mehta; Shilpa Sharma; Atul Garkal; Dattatray Yadav; Kartik Hariharan; Babeeta Shamjetshabam; Shubham Khot; Ritu Kudarha; Priyanka Bangar; Gajanan Arbade; Pratap Kalyankar

doi:10.1016/B978-0-12-822522-6.00017-5

Intranasal gene therapy for the treatment of neurological disorders

Namdev Dhas, Tejal Mehta, Shilpa Sharma, Atul Garkal, Dattatray Yadav, Kartik Hariharan, Babeeta Shamjetshabam, Shubham Khot, Ritu Kudarha, Priyanka Bangar, Gajanan Arbade, Pratap Kalyankar

Research output: Chapter in Book/Report/Conference proceeding › Chapter

9 Scopus citations

Abstract

Complex nature of central nervous system (CNS) results in difficulty to pass the drug/gene through BBB in the treatment of neurological disorders. Significant advances in targeted gene delivery have opened up ways of treating several neurological disorders across a variety of diverse modalities ranging from exogenous expression to endogenous suppression of genes. Recent nanotechnology-based advances for improved delivery of gene sequences have centered on extremely specific polymer-based gene delivery, viral vector designs, and plasmid transfection nanoparticle-based therapies. This chapter inculcates various neurological disorders and current approaches for their treatment. It also includes different challenges for intranasal gene delivery to CNS and gene delivery modalities. The authors also concentrated on several ideal properties of nanomaterials for intranasal gene delivery and various strategies involved for efficient nose-to-brain gene delivery. The chapter also put forth various factors affecting gene transportation using various nanomaterials. Nanoparticle-based approaches for intranasal gene delivery with translational medicines in the treatment of neurological disorders were also included.

Original language	English (US)
Title of host publication	Direct Nose-to-Brain Drug Delivery
Subtitle of host publication	Mechanism, Technological Advances, Applications, and Regulatory Updates
Publisher	Elsevier
Pages	351-387
Number of pages	37
ISBN (Electronic)	9780128225226
DOIs	https://doi.org/10.1016/B978-0-12-822522-6.00017-5
State	Published - Jan 1 2021
Externally published	Yes

Keywords

Gene therapy
Intranasal
Nanomaterials
Neurological disorder
Nonviral vectors
Viral vectors

ASJC Scopus subject areas

Economics, Econometrics and Finance(all)
General Business, Management and Accounting

Access to Document

10.1016/B978-0-12-822522-6.00017-5

Cite this

Dhas, N., Mehta, T., Sharma, S., Garkal, A., Yadav, D., Hariharan, K., Shamjetshabam, B., Khot, S., Kudarha, R., Bangar, P., Arbade, G., & Kalyankar, P. (2021). Intranasal gene therapy for the treatment of neurological disorders. In Direct Nose-to-Brain Drug Delivery: Mechanism, Technological Advances, Applications, and Regulatory Updates (pp. 351-387). Elsevier. https://doi.org/10.1016/B978-0-12-822522-6.00017-5

Dhas, N, Mehta, T, Sharma, S, Garkal, A, Yadav, D, Hariharan, K, Shamjetshabam, B, Khot, S, Kudarha, R, Bangar, P, Arbade, G & Kalyankar, P 2021, Intranasal gene therapy for the treatment of neurological disorders. in Direct Nose-to-Brain Drug Delivery: Mechanism, Technological Advances, Applications, and Regulatory Updates. Elsevier, pp. 351-387. https://doi.org/10.1016/B978-0-12-822522-6.00017-5

@inbook{1082a00c7f5d47b297209eb42d7e0d74,

title = "Intranasal gene therapy for the treatment of neurological disorders",

abstract = "Complex nature of central nervous system (CNS) results in difficulty to pass the drug/gene through BBB in the treatment of neurological disorders. Significant advances in targeted gene delivery have opened up ways of treating several neurological disorders across a variety of diverse modalities ranging from exogenous expression to endogenous suppression of genes. Recent nanotechnology-based advances for improved delivery of gene sequences have centered on extremely specific polymer-based gene delivery, viral vector designs, and plasmid transfection nanoparticle-based therapies. This chapter inculcates various neurological disorders and current approaches for their treatment. It also includes different challenges for intranasal gene delivery to CNS and gene delivery modalities. The authors also concentrated on several ideal properties of nanomaterials for intranasal gene delivery and various strategies involved for efficient nose-to-brain gene delivery. The chapter also put forth various factors affecting gene transportation using various nanomaterials. Nanoparticle-based approaches for intranasal gene delivery with translational medicines in the treatment of neurological disorders were also included.",

keywords = "Gene therapy, Intranasal, Nanomaterials, Neurological disorder, Nonviral vectors, Viral vectors",

author = "Namdev Dhas and Tejal Mehta and Shilpa Sharma and Atul Garkal and Dattatray Yadav and Kartik Hariharan and Babeeta Shamjetshabam and Shubham Khot and Ritu Kudarha and Priyanka Bangar and Gajanan Arbade and Pratap Kalyankar",

note = "Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-822522-6.00017-5",

language = "English (US)",

pages = "351--387",

booktitle = "Direct Nose-to-Brain Drug Delivery",

publisher = "Elsevier",

}

TY - CHAP

T1 - Intranasal gene therapy for the treatment of neurological disorders

AU - Dhas, Namdev

AU - Mehta, Tejal

AU - Sharma, Shilpa

AU - Garkal, Atul

AU - Yadav, Dattatray

AU - Hariharan, Kartik

AU - Shamjetshabam, Babeeta

AU - Khot, Shubham

AU - Kudarha, Ritu

AU - Bangar, Priyanka

AU - Arbade, Gajanan

AU - Kalyankar, Pratap

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Complex nature of central nervous system (CNS) results in difficulty to pass the drug/gene through BBB in the treatment of neurological disorders. Significant advances in targeted gene delivery have opened up ways of treating several neurological disorders across a variety of diverse modalities ranging from exogenous expression to endogenous suppression of genes. Recent nanotechnology-based advances for improved delivery of gene sequences have centered on extremely specific polymer-based gene delivery, viral vector designs, and plasmid transfection nanoparticle-based therapies. This chapter inculcates various neurological disorders and current approaches for their treatment. It also includes different challenges for intranasal gene delivery to CNS and gene delivery modalities. The authors also concentrated on several ideal properties of nanomaterials for intranasal gene delivery and various strategies involved for efficient nose-to-brain gene delivery. The chapter also put forth various factors affecting gene transportation using various nanomaterials. Nanoparticle-based approaches for intranasal gene delivery with translational medicines in the treatment of neurological disorders were also included.

AB - Complex nature of central nervous system (CNS) results in difficulty to pass the drug/gene through BBB in the treatment of neurological disorders. Significant advances in targeted gene delivery have opened up ways of treating several neurological disorders across a variety of diverse modalities ranging from exogenous expression to endogenous suppression of genes. Recent nanotechnology-based advances for improved delivery of gene sequences have centered on extremely specific polymer-based gene delivery, viral vector designs, and plasmid transfection nanoparticle-based therapies. This chapter inculcates various neurological disorders and current approaches for their treatment. It also includes different challenges for intranasal gene delivery to CNS and gene delivery modalities. The authors also concentrated on several ideal properties of nanomaterials for intranasal gene delivery and various strategies involved for efficient nose-to-brain gene delivery. The chapter also put forth various factors affecting gene transportation using various nanomaterials. Nanoparticle-based approaches for intranasal gene delivery with translational medicines in the treatment of neurological disorders were also included.

KW - Gene therapy

KW - Intranasal

KW - Nanomaterials

KW - Neurological disorder

KW - Nonviral vectors

KW - Viral vectors

UR - http://www.scopus.com/inward/record.url?scp=85121734128&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85121734128&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-822522-6.00017-5

DO - 10.1016/B978-0-12-822522-6.00017-5

M3 - Chapter

AN - SCOPUS:85121734128

SP - 351

EP - 387

BT - Direct Nose-to-Brain Drug Delivery

PB - Elsevier

ER -

Intranasal gene therapy for the treatment of neurological disorders

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this